Exicure Stock (NASDAQ:XCUR)

Forecast Ownership Financials Chart

Previous Close

$4.31

52W Range

$2.15 - $36.00

50D Avg

$5.33

200D Avg

$9.20

Market Cap

$33.61M

Avg Vol (3M)

$50.11K

Beta

3.77

Div Yield

XCUR Company Profile

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 22, 2018

Website

XCUR Performance

XCUR Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$500.00K	-	$28.83M
Operating Income	$-12.23M	$-15.00M	$-1.83M
Net Income	$-9.70M	$-16.91M	$-2.58M
EBITDA	-	$-15.54M	$78.00K
Basic EPS	$-4.75	$-2.11	$-0.56
Diluted EPS	$-4.75	$-2.11	$-0.56

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
DMAC	DiaMedica Therapeutics Inc.
ATXI	Avenue Therapeutics, Inc.
SLNO	Soleno Therapeutics, Inc.
DYAI	Dyadic International, Inc.
HOTH	Hoth Therapeutics, Inc.

Exicure Stock (NASDAQ:XCUR)

XCUR Company Profile

XCUR Performance

XCUR Financial Summary

Peer Comparison

Start a conversation